Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review
Curr Gene Ther. 2024 Jan 2. doi: 10.2174/0115665232266508231210154930. Online ahead of print.ABSTRACTHashimoto's thyroiditis (HT) is a commonly occurring illness of autoimmune endocrine origin. It is usually present in the pediatric age group along with other well-known diseases, such as type 1 insulin-dependent diabetes. The defining feature of this disease is the immune-- mediated attack on the thyroid gland resulting in the destruction of thyroid tissues and cells. Given that HT frequently affects family members, it is well-recognized that individuals are genetically predisposed to this disease. Patients with HT also di...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Apoorva Upreti Sayali Mukherjee Source Type: research
Segmentation of Thoracic Organs through Distributed Extraction of Visual Feature Patterns Utilizing Resio-Inception U-Net and Deep Cluster Recognition Techniques
In this study, we present a new segmentation method that meets the difficulties posed by sophisticated organ shapes in computed tomography (CT) images, particularly targeting lung, breast, and gastric cancers. Our suggested methods, Resio-Inception U-Net and Deep Cluster Recognition (RIUDCR), use a Residual Inception Architecture, which combines the power of residual connections and inception blocks to achieve cutting-edge segmentation performance while reducing the risk of overfitting. We present mathematical equations and functions that describe the design, including the encoding and decoding steps within the UC-Net syst...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Karthikeyan S Tathagat Banerjee Devi Priya Meenalosini Vimal Cruz Source Type: research
Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF
Conclusion: DBIL, but not IBIL, was associated with short-term ominous prognosis in patients with HFpEF. Hence, DBIL may be the superior predictor for prognosis in HFpEF.PMID:38310459 | DOI:10.2174/0115665232273115240102043640 (Source: Current Gene Therapy)
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Sunying Wang Yan Chen Hanghao Ma Yuwei Wang Manqing Luo Xianwei Xie Qingyong Yang Kaijin Lin Meihua Lin Lin Lin Ping Chen Qiaowen Zheng Fuqing Sun Source Type: research
Potential Therapeutic Approach Using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease
Curr Gene Ther. 2024 Jan 19. doi: 10.2174/0115665232283842240102073002. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative illness characterized by specific loss of dopaminergic neurons, resulting in impaired motor movement. Its prevalence is twice as compared to the previous 25 years and affects more than 10 million individuals. Lack of treatment still uses levodopa and other options as disease management measures. Treatment shifts to gene therapy (GT), which utilizes direct delivery of specific genes at the targeted area. Therefore, the use of aromatic L-amino acid decarboxylase (AADC) and glia...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Raman Kumar Tripathi Lav Goyal Shamsher Singh Source Type: research
CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine
Curr Gene Ther. 2024 Jan 2. doi: 10.2174/0115665232275754231204072320. Online ahead of print.ABSTRACTWith the discovery of CRISPR-Cas9, drug development and precision medicine have undergone a major change. This review article looks at the new ways that CRISPR-based therapies are being used and how they are changing the way medicine is done. CRISPR technology's ability to precisely and flexibly edit genes has opened up new ways to find, validate, and develop drug targets. Also, it has made way for personalized gene therapies, precise gene editing, and advanced screening techniques, all of which hold great promise for treat...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Dilip Kumar Chanchal Jitendra Singh Chaudhary Pushpendra Kumar Neha Agnihotri Prateek Porwal Source Type: research
Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review
Curr Gene Ther. 2024 Jan 2. doi: 10.2174/0115665232266508231210154930. Online ahead of print.ABSTRACTHashimoto's thyroiditis (HT) is a commonly occurring illness of autoimmune endocrine origin. It is usually present in the pediatric age group along with other well-known diseases, such as type 1 insulin-dependent diabetes. The defining feature of this disease is the immune-- mediated attack on the thyroid gland resulting in the destruction of thyroid tissues and cells. Given that HT frequently affects family members, it is well-recognized that individuals are genetically predisposed to this disease. Patients with HT also di...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Apoorva Upreti Sayali Mukherjee Source Type: research
Segmentation of Thoracic Organs through Distributed Extraction of Visual Feature Patterns Utilizing Resio-Inception U-Net and Deep Cluster Recognition Techniques
In this study, we present a new segmentation method that meets the difficulties posed by sophisticated organ shapes in computed tomography (CT) images, particularly targeting lung, breast, and gastric cancers. Our suggested methods, Resio-Inception U-Net and Deep Cluster Recognition (RIUDCR), use a Residual Inception Architecture, which combines the power of residual connections and inception blocks to achieve cutting-edge segmentation performance while reducing the risk of overfitting. We present mathematical equations and functions that describe the design, including the encoding and decoding steps within the UC-Net syst...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Karthikeyan S Tathagat Banerjee Devi Priya Meenalosini Vimal Cruz Source Type: research
Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF
Conclusion: DBIL, but not IBIL, was associated with short-term ominous prognosis in patients with HFpEF. Hence, DBIL may be the superior predictor for prognosis in HFpEF.PMID:38310459 | DOI:10.2174/0115665232273115240102043640 (Source: Current Gene Therapy)
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Sunying Wang Yan Chen Hanghao Ma Yuwei Wang Manqing Luo Xianwei Xie Qingyong Yang Kaijin Lin Meihua Lin Lin Lin Ping Chen Qiaowen Zheng Fuqing Sun Source Type: research
Potential Therapeutic Approach Using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease
Curr Gene Ther. 2024 Jan 19. doi: 10.2174/0115665232283842240102073002. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative illness characterized by specific loss of dopaminergic neurons, resulting in impaired motor movement. Its prevalence is twice as compared to the previous 25 years and affects more than 10 million individuals. Lack of treatment still uses levodopa and other options as disease management measures. Treatment shifts to gene therapy (GT), which utilizes direct delivery of specific genes at the targeted area. Therefore, the use of aromatic L-amino acid decarboxylase (AADC) and glia...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Raman Kumar Tripathi Lav Goyal Shamsher Singh Source Type: research
CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine
Curr Gene Ther. 2024 Jan 2. doi: 10.2174/0115665232275754231204072320. Online ahead of print.ABSTRACTWith the discovery of CRISPR-Cas9, drug development and precision medicine have undergone a major change. This review article looks at the new ways that CRISPR-based therapies are being used and how they are changing the way medicine is done. CRISPR technology's ability to precisely and flexibly edit genes has opened up new ways to find, validate, and develop drug targets. Also, it has made way for personalized gene therapies, precise gene editing, and advanced screening techniques, all of which hold great promise for treat...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Dilip Kumar Chanchal Jitendra Singh Chaudhary Pushpendra Kumar Neha Agnihotri Prateek Porwal Source Type: research
Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review
Curr Gene Ther. 2024 Jan 2. doi: 10.2174/0115665232266508231210154930. Online ahead of print.ABSTRACTHashimoto's thyroiditis (HT) is a commonly occurring illness of autoimmune endocrine origin. It is usually present in the pediatric age group along with other well-known diseases, such as type 1 insulin-dependent diabetes. The defining feature of this disease is the immune-- mediated attack on the thyroid gland resulting in the destruction of thyroid tissues and cells. Given that HT frequently affects family members, it is well-recognized that individuals are genetically predisposed to this disease. Patients with HT also di...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Apoorva Upreti Sayali Mukherjee Source Type: research
Segmentation of Thoracic Organs through Distributed Extraction of Visual Feature Patterns Utilizing Resio-Inception U-Net and Deep Cluster Recognition Techniques
In this study, we present a new segmentation method that meets the difficulties posed by sophisticated organ shapes in computed tomography (CT) images, particularly targeting lung, breast, and gastric cancers. Our suggested methods, Resio-Inception U-Net and Deep Cluster Recognition (RIUDCR), use a Residual Inception Architecture, which combines the power of residual connections and inception blocks to achieve cutting-edge segmentation performance while reducing the risk of overfitting. We present mathematical equations and functions that describe the design, including the encoding and decoding steps within the UC-Net syst...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Karthikeyan S Tathagat Banerjee Devi Priya Meenalosini Vimal Cruz Source Type: research
Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF
Conclusion: DBIL, but not IBIL, was associated with short-term ominous prognosis in patients with HFpEF. Hence, DBIL may be the superior predictor for prognosis in HFpEF.PMID:38310459 | DOI:10.2174/0115665232273115240102043640 (Source: Current Gene Therapy)
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Sunying Wang Yan Chen Hanghao Ma Yuwei Wang Manqing Luo Xianwei Xie Qingyong Yang Kaijin Lin Meihua Lin Lin Lin Ping Chen Qiaowen Zheng Fuqing Sun Source Type: research
Potential Therapeutic Approach Using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease
Curr Gene Ther. 2024 Jan 19. doi: 10.2174/0115665232283842240102073002. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative illness characterized by specific loss of dopaminergic neurons, resulting in impaired motor movement. Its prevalence is twice as compared to the previous 25 years and affects more than 10 million individuals. Lack of treatment still uses levodopa and other options as disease management measures. Treatment shifts to gene therapy (GT), which utilizes direct delivery of specific genes at the targeted area. Therefore, the use of aromatic L-amino acid decarboxylase (AADC) and glia...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Raman Kumar Tripathi Lav Goyal Shamsher Singh Source Type: research
CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine
Curr Gene Ther. 2024 Jan 2. doi: 10.2174/0115665232275754231204072320. Online ahead of print.ABSTRACTWith the discovery of CRISPR-Cas9, drug development and precision medicine have undergone a major change. This review article looks at the new ways that CRISPR-based therapies are being used and how they are changing the way medicine is done. CRISPR technology's ability to precisely and flexibly edit genes has opened up new ways to find, validate, and develop drug targets. Also, it has made way for personalized gene therapies, precise gene editing, and advanced screening techniques, all of which hold great promise for treat...
Source: Current Gene Therapy - February 4, 2024 Category: Genetics & Stem Cells Authors: Dilip Kumar Chanchal Jitendra Singh Chaudhary Pushpendra Kumar Neha Agnihotri Prateek Porwal Source Type: research
